Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Rating of “Hold” from Analysts

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has received an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $3.75.

A number of equities analysts have recently commented on HOWL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, January 21st. Wedbush lowered shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research note on Friday, December 19th. Citizens Jmp downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Finally, HC Wainwright cut their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, December 19th.

Werewolf Therapeutics Stock Down 3.1%

HOWL opened at $0.84 on Friday. The firm has a market cap of $40.92 million, a P/E ratio of -0.52 and a beta of 0.78. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The business has a 50 day moving average price of $0.66 and a 200 day moving average price of $1.05. Werewolf Therapeutics has a twelve month low of $0.53 and a twelve month high of $2.38.

Insider Activity at Werewolf Therapeutics

In related news, Director Luke Evnin sold 108,606 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66. Following the completion of the transaction, the director owned 2,550,674 shares of the company’s stock, valued at approximately $1,555,911.14. The trade was a 4.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 682,097 shares of company stock valued at $415,797 in the last 90 days. Insiders own 23.60% of the company’s stock.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP lifted its holdings in shares of Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after buying an additional 13,439 shares during the last quarter. Vontobel Holding Ltd. boosted its position in shares of Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares during the period. Regal Investment Advisors LLC grew its stake in shares of Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter worth $28,000. Finally, Bank of America Corp DE increased its position in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.